Drug-eluting stents

Stent directo, sin utilidad clínica en pacientes electivos (en)

solaci
solaci
424
0

Previous article
Double DES in bifurcations, double thrombosis risk
Next article
Direct Stent, no clinical utility in patients undergoing elective
solaci
solaci

More articles by this author

EuroPCR 2026 | Are bioresorbable stents making a comeback? Five-year results of FUTURE-II with Firesorb

Dr. Juan Manuel Pérez - 0
The first bioresorbable coronary scaffolds generated great expectations because of their potential to restore vascular physiology after device resorption. However, early studies such as...

EuroPCR 2026 | Coronary bioadaptor: fewer events regardless of IVUS or FFR guidance

Dr. Juan Manuel Pérez - 0
Despite the increasing use of intracoronary imaging and physiology, stent-related events continue to occur at an annual rate of approximately 2–3% beyond the first...

EuroPCR 2026 | Is localized anticoagulation the next step for coronary stents?

Dr. Juan Manuel Pérez - 0
The DESyne BDS Plus stent was developed as a thin-strut, bioabsorbable polymer drug-eluting stent that combines sirolimus release with two anticoagulant agents (rivaroxaban and...

EuroPCR 2026 | Restoring vascular physiology: 4-year results of the BIOADAPTOR-RCT

Dr. Juan Manuel Pérez - 0
Despite advances in drug-eluting stents, device-related events continue to increase beyond the first year after angioplasty. In this context, the DynamX system emerged as...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Coronary disease

EuroPCR 2026 | Are bioresorbable stents making a comeback? Five-year results of FUTURE-II with Firesorb

The first bioresorbable coronary scaffolds generated great expectations because of their potential to restore vascular physiology after device resorption. However,...
Dr. Juan Manuel Pérez -
SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Dr. Omar Tupayachi - 0
Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Dr. Juan Manuel Pérez - 0
Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

Dr. Andrés Rodríguez - 0
After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...